A fortune 500 global leading pharmaceutical company specialized in generic drugs was looking for Regulatory support in filing MAA and baseline submissions to the health authorities of Switzerland and GCC. The challenge was to track all the revisions made to the documents in an incremental basis.

Read through the case study to decode how Freyr played a vital role in accelerating the submission process for swift approvals.